Thymopentin
Published · Researched 2026-09-21
Overview
Thymopentin (TP5) is the synthetic pentapeptide Arg-Lys-Asp-Val-Tyr — residues 32–36 of the hormone thymopoietin — retaining the parent hormone's T-cell differentiation activity. It is an approved therapeutic agent in China (used for rheumatoid arthritis, immunodeficiency/AIDS, chronic hepatitis B) and is also used in dermatology under names like Sintomodulina (topical for atopic dermatitis, contact dermatitis, psoriasis). A 2025 Biomedicines paper revived interest with murine data on thymic rejuvenation and enhanced T-cell antitumor immunity.
Social standing
- Thin 2026 social signal. Thymopentin appears in the EU vendor layer (peptide-products.com lists THYMOPENTIN 10 mg) and in science-communication summaries of the 2025 thymic-rejuvenation mouse study, but no dedicated owner-discussion, anecdotes, or Threads/Facebook Group threads were found in this research pass.
- Retailer layer: peptide-products.com (EU) — THYMOPENTIN 10 mg €52.00, sold as "thymus polypeptide with immunomodulatory properties … able to induce interferons."
- Recurring praise (where mentioned): China's clinical approval gives it a stronger medical track record than most gray-market immune peptides; dermatology use broadens the story.
- Recurring complaints/failure modes: near-zero Western community discussion; no US gray-market ecosystem; 2025 antitumor data is murine only.
- Representative quotes: none with attributable peer-owner provenance.
Social validation
Tier 3 / UNVALIDATED — no two independent social sources with item-level discussion found. Signals are retailer listings and science reporting only. Included for research completeness (one of the few thymic peptides with real drug approval in a major jurisdiction), not social demand.
Key specs table
| Property | Value |
|---|---|
| Identity | Arg-Lys-Asp-Val-Tyr (thymopoietin residues 32–36), TP5 |
| Formula / MW | C30H49N9O9 / 679.8 g/mol |
| CAS | 69558-55-0 |
| Origin | Synthetic active site of thymopoietin (Goldstein; US Pat. 4,190,646) |
| Mechanism (reported) | Promotes T-cell phenotypic differentiation; modulates immune responses; murine data: thymic rejuvenation, enhanced effector cytokine production, downregulated inhibitory receptors |
| Forms | Pharma (China): injectable; Dermatology: topical (Sintomodulina/sh-Pentapeptide-1). Gray market: 10 mg research vials (EU) |
| Community-reported dosing | None observed — no community protocols found |
Pricing
- EU retail (observed 2026-09-20): peptide-products.com — THYMOPENTIN 10 mg €52.00.
- China pharma: approved drug; 2026 retail pricing UNVERIFIED.
- Facebook Marketplace: no used listings observed — say so plainly (none found).
What's included / what's needed
Gray-market EU listing: 10 mg lyophilized vial; reconstitution supplies (bacteriostatic water/sterile saline, syringes) needed, not included. Pharma injectable (China): ampoules/vials per national labeling.
Support reality
EU retail distribution (peptide-products.com) with standard shop support. China-market pharma products distributed domestically; no Western community support infrastructure. No US gray-market vendors widely stocking it as of this writing.
Community verdict
Thymopentin is the "approved drug nobody talks about" — an actual China-approved immunomodulator with a real clinical record, but effectively absent from Western peptide social culture. The 2025 mouse thymic-rejuvenation data gives it a second narrative wind, though it's preclinical. For buyers prioritizing regulatory pedigree, it's arguably the most credentialed thymic peptide here — and the least discussed.
Regulatory & safety status
Approved drug in China (RA, AIDS, chronic hepatitis B) and used in dermatology (topical Sintomodulina) — NOT FDA-approved, no EMA approval. Gray-market "Thymopentin" vials are research chemicals not for human use. Safety signals (observed): decades of China-market use per literature; Russian/dermatology use reports mild local reactions; no Western safety database for gray-market product. Never imply US/EU human-use approval.
Image view breakdown
0/8 views obtained — no Thymopentin-specific real product photos found. Image searches returned mislabeled thymosin-alpha-1 vials, untraceable editorial stock, and unrelated images; per the honest-image rule, none were used. Missing: all eight views (hero, side, rear, top, detail, inuse, scale, box).
Not medical advice. This is a research summary of publicly discussed information, not a recommendation to use any substance.
Named sources
- Biomedicines — 2025 Biomedicines paper revived interest with murine thymic-rejuvenation data (2025)
- peptide-products.com — lists THYMOPENTIN 10 mg) and in science-communication summaries of the 2025 thymic-rejuvenation mouse study, but no dedicated (2025)
Source URLs were not recorded for these references.